Advanced Courses

ESMO-ESO Courses on Medical Oncology for Medical Students

These annual five-day residential courses enable students to get a full picture of this challenging and interesting professional field before making the choice of their specialisation.

Preceptorship Courses

Apply now to join one of our Preceptorship courses!

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

EFPIA Disclosure Code

Policy News

Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!

CancerSEEK Promises Earlier Detection of Cancer

Researchers from the John Hopkins Kimmel Cancer Center in Baltimore, Maryland, USA reported on 18 January 2018 in Science results of blood test, called CancerSEEK, applied to 1,005 patients with non-metastatic, clinically detected eight common cancer types: ovarian, liver, stomach, pancreatic, oesophageal, colorectal, lung, and breast. The test assesses the levels of circulating proteins and mutations in cell-free DNA and was positive in a median of 70% of these eight cancer types.

The study authors wrote in background that earlier detection of cancer is key in reducing cancer-related deaths. The first component of CancerSEEK determines mutations in cell-free DNA. The second component is determining levels of protein biomarkers. The algorithm in the study then used machine-learning tools and statistical analyses to determine the median sensitivity and specificity of the test.

With purified DNA from plasma, the researchers amplified the sample with multiplex–polymerase chain reaction using a robust 61-amplicon panel that had the ability to detect rare mutations. The 61 primer pairs were designed to amplify 66 to 80 base-pair segments of the DNA in regions of interest from 16 genes. The amplified products were uniquely labelled with a DNA barcode and were matched to reference sequences present in the Catalogue of Somatic Mutations in Cancer dataset or ones that were predicted to be inactivating mutations in tumour suppressor cells.

The second component of the test is determining levels of protein biomarkers. The reason for incorporating this step is that early-stage tumours do not release detectable circulating tumour DNA. The eight proteins measured are CA 125, CEA, CA 19-9, prolactin, hepatocyte growth factor, osteopontin, myeloperoxidase, and tissue inhibitor of metalloproteinases 1.

For the study, the researchers recruited 1,005 patients with median age at diagnosis of 64 years. The most common stage of disease at presentation was stage II (49%), 20% of patients had stage I cancer, and 31% of patients had stage III disease. The study also included a control group of 812 healthy individuals with median age of 55 years, who had no history of cancer.

The median overall sensitivity of the test was 70% for the eight common cancers. The sensitivities of CancerSEEK ranged from 69% to 98% for the detection of five cancer types (ovarian, liver, stomach, pancreatic, and oesophageal) for which there are no screening tests available for average-risk individuals.

The median sensitivity of CancerSEEK was 73% for stage II cancers, 78% for stage III cancers, and 43% for stage I cancers. For stage I cancers, the highest sensitivity was for liver cancer (100%), and the lowest was for oesophageal cancer (20%).

The specificity of CancerSEEK was more than 99%. The study team pointed out that only 7 of 812 healthy controls scored positive.

In addition, CancerSEEK localised the cancer to a small number of anatomic sites in a median of 83% of the patients.

There are several limitations of this study, the key one is that patients with known cancers were enrolled. The vision would be to use the test in asymptomatic individuals to screen for cancer. The Johns Hopkins collaborates in that regard with the Geisinger Health System in Pennsylvania; they have already started to use the test on blood samples from female volunteers aged between 65 and 75 years who have never had cancer. This 5-year study of up to 50,000 women is funded by a private philanthropic group, The Marcus Foundation.

The current test is not ready for clinic yet. However, the study findings published in Science lay the conceptual foundation for a single, multi-analyte blood test for early detection of many types of cancers. The researchers concluded that for establishing the clinical utility of CancerSEEK, prospective studies of all incident cancer types in a large population are required.